Clinical Trials

Accrual Status
Limit to SWOG Trials

654 Results

Active Filters

Closed
Phase
Accrual
76%
Published
SWOG Clinical Trial Number
SWOG-8945
Closed
Phase
Accrual
100%
Published
Closed
Phase
Accrual
72%
Published
SWOG Clinical Trial Number
SWOG-8911
Closed
Phase
Accrual
45%
Published
SWOG Clinical Trial Number
SWOG-8834

A Phase II Evaluation of Fazarabine in Central Nervous System Tumors

Research Committee(s)
Brain Cancer
Activated
07-01-1990
Closed
12-01-1991
Closed
Phase
Accrual
83%
Published
SWOG Clinical Trial Number
SWOG-8930
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-8957
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-8929
Closed
Phase
Accrual
70%
Published
SWOG Clinical Trial Number
SWOG-8902
Closed
Phase
Accrual
90%
Published
Closed
Phase
Accrual
80%
Published
Closed
Phase
Accrual
86%
Published
SWOG Clinical Trial Number
SWOG-8916

Evaluation of Merbarone in Pancreatic Adenocarcinoma

Activated
03-15-1990
Closed
06-15-1991
Closed
Phase
Accrual
48%
Published
SWOG Clinical Trial Number
SWOG-8944
Closed
Phase
Accrual
49%
Published
SWOG Clinical Trial Number
SWOG-8866
Closed
Phase
Accrual
63%
Published
Closed
Phase
Accrual
100%
Published
Closed
Phase
Accrual
100%
Published
Closed
Phase
Accrual
60%
Published
SWOG Clinical Trial Number
SWOG-8923

Neo-FAC for Poor Prognosis Stage IV Breast Cancer, A Phase II Pilot Study

Research Committee(s)
Breast Cancer
Activated
02-15-1990
Closed
06-01-1992
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-8921

Trials of Cyclophosphamide, IL-2, DTIC/IL-2, and DTIC/Cisplatin/Tamoxifen in Stage IV Melanoma

Research Committee(s)
Melanoma
Activated
02-15-1990
Closed
09-01-1991
Closed
Phase
Published
SWOG Clinical Trial Number
SWOG-8994 (EST-C-0690) (INT-0086)
Closed
Phase
Accrual
63%
Published
SWOG Clinical Trial Number
SWOG-8906

Evaluation of Merbarone in Hepatoma, Phase II

Activated
02-01-1990
Closed
05-01-1992